Biotech | September 29, 2025
DINAMIQS inaugurates new cGMP viral vector manufacturing facility in Switzerland
The new site enables end-to-end production of viral vector gene therapies
The new site enables end-to-end production of viral vector gene therapies
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
New infrastructure makes it possible for healthcare organizations to integrate AI agents seamlessly into critical workflows like benefit verification and prior authorization
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
The positive opinion is based on results from KOMET, the largest and only placebo-controlled, double-blind global Phase III trial in this patient population
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Subscribe To Our Newsletter & Stay Updated
